What’s Wrong with this Picture? Focus on Contract Manufacturing

May 6, 2020

We’ve talked about this before. Possibly the most opaque element of the dietary supplement supply chain is the contract manufacturer.

Arguably, contract manufacturers have the largest role in the production of a dietary supplement, but rarely are they identified to the consumer purchasing the product. Too frequently, consumer inquiries relating to manufacturing and manufacturers are met with a brand response of “that is proprietary information.” It is still standard practice for most brands to not disclose the name of their manufacturer to an inquiring consumer.

When Trust Transparency Center asked executives about this practice, responses have centered around the concern of competitors going to that manufacturer and reverse engineering their product.

This is not really a legitimate concern if they’ve got the right manufacturer in the first place. Consumers and retailers have a right to know where, and under what conditions a product is made. We expect increased demand for this transparency as our new normal leads to supply chain upheavals that can make product unavailable and workers increasingly obtain a voice that may in fact contribute to supply chain changes and disruption. Companies that do not exercise transparency in this environment are making a potential asset into a liability.

There are at least two hundred dietary supplement contract manufacturers in the United States, yet most of them have limited engagement with the rest of industry. This is manifest by lack of association involvement and poor engagement with groups such as the American Botanical Council and others providing benchmarking, education and practice guidance. Can you legitimately expect those that shirk these activities, refusing to engage with peers and experts to be the best and most compliant organizations to work with?

But, the U.S. FDA does spend a lot of time and resources on contract manufacturers. Most recently, it unveiled the FDA Data Dashboard, a tool that allows any user to see the inspection history between it and a manufacturer.

The most recent widely searched and discussed contract manufacturer is ABH Nature’s Products. The US Department of Justice in cooperation with the FDA recently implemented a recall of all products produced at ABH because of the firm’s refusal to take corrective action for violations referenced in seven inspections occurring over ten years [see below charts for detail.

In looking at all FDA’s inspection data from 2009-2019, FDA reportedly identified 1,105 violations requiring “Official Action” of Food/Cosmetics products, which is the category dietary supplement contract manufacturers reside within this database.

ABH was not alone in receiving repeated violations over several inspections. One CEO of a national brand, who we’ll allow to remain anonymous, was contacted in relation to this topic and we at TTC have advised him that his contract manufacturer is in a similar situation as ABH—case in point the data on the CM from the FDA dashboard.

TTC was told the brand was aware of the FDA cited deficiencies reported over the years. It has been realized, and presumably accepted in this case, that the CM was not following GMP as indicated by the numerous FDA inspections. In this case though, the brand chose not to change suppliers, and to simply provide postproduction third-party testing to ensure the purity and safety of the products produced – technically a fix.

However, even had ABH customers taken these same actions regarding post-production testing, the FDA would still have ordered its recall because the contract manufacturer is responsible for GMP compliance of its manufacturing operations. A workaround for those deficiencies is not a fundamental answer for compliance or best practices. This needs to change.

In analyzing the FDA database, TTC identified over 50 other contract manufacturers that have received three or more Official Action Indicated (OFI) citations from three or more inspections over recent years. Many of the FDA citations were repeated violations. Some of the companies have been closed by the FDA through injunctions – but not enough. 

This database access is relatively new. The information contained in the database does reinforce the fact that many more contract manufacturers follow FDA cGMP than do not, and it calls out specifically those in violation. The database information allows for a greater degree of transparency into FDA inspections than has been provided previously, and any brand making a choice, and any retailer taking the gatekeeper role seriously should use this database to be more informed and potentially avoid an ABH type event in the future.

Key points to take away:

  • It is your right, and it is best practice to ask about the inspection history of your supply chain partners and to audit them. Lack of clarity and transparency is a giveaway that something is likely wrong.
  • Asking how suppliers, including contract manufacturers, are selected will provide huge insights into culture, compliance and commitment. Asking about the circumstances surrounding the last supplier that was ‘dumped’ is a good practice.
  • The FDA Data Dashboard provides good intelligence and should be used as a risk management tool.
  • Supply chain transparency and establishing trust along the chain is more than a risk management strategy. It should be used as an asset.

Related Articles & Resources

Unlock the Power of Transparency: Schedule a Meeting Now

Ready to Illuminate Your Path?
Partner with Trust Transparency Today.

Get inTouch

Lori Diez

Lori Diez combines compassion and excellence to lead organizations to their next level. A small-town Texas childhood taught her the value of hard work and relationships, which she uses to foster teamwork that brings results that have transformed cultures and programs to their highest potential. Her successful career in pharmaceutical and nutraceutical sales leadership and event hosting has prepared her to deliver results as the COO of TrustTransparency, where she uses her industry knowledge to ensure that the company’s operations run smoothly as they support nutraceutical companies in their mission to help others. Lori’s passion for charity reflects her belief that individuals working together can change the world, no matter how small their contribution to the effort. This year, she looks forward to continuing over a decade of service at the Houston Livestock Show And Rodeo, where she will be the Chairman of the Livestock Committee.

Conference Handouts

Conference Handouts

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 Case Study

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 (1)

Statin Q10 Effect Case Study

Statin Q10 Effect Case Study

Schedule Consultation with Trust Transparency

Glynnda Steinford

Glynnda Steinford, Trust Transparency Consulting’s Director of Customer Relations, brings over four decades of healthcare experience to her vital role in client engagement and relationship building. Her diverse background spans from administering medical groups to impactful stints in pharmaceutical and nutraceutical sales, all underlined by her degree in Healthcare Administration.

At the heart of Glynnda’s work is her talent for nurturing long-term connections, a skill she leverages to enhance client experiences and partnerships within the consultancy. Beyond her professional commitments, she enjoys life’s simple pleasures, whether it’s her love for cats and cooking or her ventures into golf, always prioritizing cherished moments with family and friends. Her personal interests echo the dedication and warmth she extends in her professional network, making her an invaluable asset to the team.

Caiti Dowden

Caiti Dowden stands as a crucial pillar at Trust Transparency Consulting, bringing invaluable insight and expertise to her role as Senior Executive Assistant’ since her start in 2018. With an academic background from Sam Houston University and a career shift from education to the nutraceutical sphere in 2010, Caiti has cultivated a sharp acumen for dissecting industry trends and bolstering strategic decision-making.

Her transition from Data Analyst reflects her growth and deep understanding of the business landscape. Caiti’s commitment goes beyond professional excellence; she thrives on balance, drawing from her rich life outside of work to enhance her organizational contributions. Whether it’s family time, volunteering, or rooting for Houston’s sports teams, she believes in embracing experiences to fuel her professional creativity and insight.

In her current role, Caiti’s dedication to dynamic business analysis and operational support proves her to be an irreplaceable asset to our team, embodying the synergy of personal enrichment and professional success.

Pam Hilpert

Pam Hilpert, Chief of Staff at Trust Transparency Consulting, has been instrumental in the firm since its inception, leveraging her 17 years of accounting experience, including a significant tenure in the nutrition sector. Her collaboration with Scott Steinford spans various successful ventures, emphasizing her integral role in the company’s financial and strategic initiatives.

An alumnus of Sam Houston State University, Pam holds degrees in both Business Administration and Accounting, as well as an MBA, adding academic heft to her practical industry insights. Beyond her professional prowess, Pam is passionate about family, enjoys live music, delves into quilting, and volunteers at her church, reflecting her well-rounded life.

Her multifaceted expertise and longstanding dedication make Pam a cornerstone of Trust Transparency Consulting’s operational strength and team unity.

Scott Steinford

Scott Steinford, a trailblazer in strategic leadership, boasts a certified M&A background, having navigated companies from their genesis to industry prominence. His brainchild, Trust Transparency Consulting, born in 2007, stands as a testament to his dedication to ethical business practices and strategic foresight, offering industry stakeholders invaluable guidance.

Beyond founding and steering companies, Scott has enriched the business landscape with his insightful keynotes and prolific written contributions, emphasizing his commitment to elevating industry standards. His executive tenure shines in roles as CEO or President of for-profits like ZMC-USA and Doctor’s Best, extending to significant contributions in non-profit sectors.

Notably, Scott’s influence is a driving force in the CoQ10 market, where his leadership has significantly bolstered the ingredient’s global presence. His roles in various capacities, including as a New Hope Ambassador, keep the community informed, providing in-depth industry reports and insights.

An active advocate within professional associations and an Editorial Advisor for leading industry publications, Scott’s expertise is both recognized and sought after. With academic roots in Pre-Law and a Master’s in Law, his journey transcends textbooks, embodying real-world business acumen and transformative leadership.

Scott Steinford merges visionary entrepreneurship with principled leadership, creating a legacy of innovation, growth, and unwavering commitment to industry excellence.